MannKind Corp (NAS:MNKD)

$ 6.61 -0.06 (-0.9%) Market Cap: 1.84 Bil Enterprise Value: 1.83 Bil PE Ratio: 83.38 PB Ratio: 0 GF Score: 74/100

Q3 2024 MannKind Corp Earnings Call Transcript
Nov 07, 2024

$7.39 (-0.67%)

Earnings
Q2 2024 MannKind Corp Earnings Call Transcript
Aug 07, 2024

$5.01 (-4.93%)

Earnings
Q1 2024 MannKind Corp Earnings Call Transcript
May 08, 2024

$4.4 (-1.57%)

Earnings
Q4 2023 MannKind Corp Earnings Call Transcript
Feb 27, 2024

$3.78 (+5.59%)

Earnings
MannKind Corp at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
MannKind Corp to Discuss the Purchase of Tyvaso DPI by Sagard Healthcare Transcript
Jan 03, 2024
Q3 2023 MannKind Corp Earnings Call Transcript
Nov 07, 2023

$3.8 (+3.26%)

Earnings
MannKind Corp at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 27, 2023
MannKind Corp at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Q2 2023 MannKind Corp Earnings Call Transcript
Aug 07, 2023

$4.6 (-2.54%)

Earnings
Q1 2023 MannKind Corp Earnings Call Transcript
May 09, 2023

$3.8 (-2.06%)

Earnings
Q4 2022 MannKind Corp Earnings Call Transcript
Feb 23, 2023

$5.22 (+0.58%)

Earnings
MannKind Corp at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Q3 2022 MannKind Corp Earnings Call Transcript
Nov 08, 2022

$3.81 (+4.96%)

Earnings
Q2 2022 MannKind Corp Earnings Call Transcript
Aug 09, 2022

$4.09 (-5.98%)

Earnings
MannKind Corp at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2022
Q1 2022 MannKind Corp Earnings Call Transcript
May 05, 2022

$3.07 (-4.95%)

Earnings
MannKind Corp at Lytham Partners Spring Investor Conference (Virtual) Transcript
Apr 04, 2022
Q4 2021 MannKind Corp Earnings Call Transcript
Feb 24, 2022

$2.91 (-20.49%)

Earnings
MannKind Corp at Lytham Partners Winter Investor Conference (Virtual) Transcript
Dec 13, 2021
Q3 2021 MannKind Corp Earnings Call Transcript
Nov 09, 2021

$4.8 (-0.83%)

Earnings
MannKind Corp at Lytham Partners Fall Investor Conference (Virtual) Transcript
Oct 05, 2021
Q2 2021 MannKind Corp Earnings Call Transcript
Aug 11, 2021

$3.99 (+2.57%)

Earnings
MannKind Corp Annual Shareholders Meeting Transcript
May 20, 2021
Q1 2021 MannKind Corp Earnings Call Transcript
May 12, 2021

$4.02 (-8.64%)

Earnings
Q4 2020 MannKind Corp Earnings Call Transcript
Feb 25, 2021

$5.61 (-6.19%)

Earnings
Q3 2020 MannKind Corp Earnings Call Transcript
Nov 04, 2020

$2.07 (+0.98%)

Earnings
Q2 2020 MannKind Corp Earnings Call Transcript
Aug 05, 2020

$1.86 (+12.05%)

Earnings
MannKind Corp Annual Shareholders Meeting Transcript
May 21, 2020
Q1 2020 MannKind Corp Earnings Call Transcript
May 06, 2020

$1.32 (-1.49%)

Earnings
MannKind Corporation - Special Call Transcript
Apr 15, 2020
Q4 2019 MannKind Corp Earnings Call Transcript
Feb 25, 2020

$1.35 (-11.18%)

Earnings
Q3 2019 MannKind Corp Earnings Call Transcript
Nov 06, 2019

$1.32 (-11.41%)

Earnings
Q2 2019 MannKind Corp Earnings Call Transcript
Aug 07, 2019

$1.12 (+3.70%)

Earnings
Q1 2019 MannKind Corp Earnings Call Transcript
May 07, 2019

$1.45 (-6.45%)

Earnings
Q4 2018 MannKind Corp Earnings Call Transcript
Feb 26, 2019

$1.76 (+16.56%)

Earnings

MannKind Corp at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 07:15PM GMT

Release Date Price: $4.98 (+2.68%)

Transcript

Unidentified Analyst

Hello, all. Welcome. My name is [Tousy Kuwash], and I'm an associate at JPMorgan. It's my pleasure to welcome our speaker for today, Michael Castagna, CEO of MannKind.

And with that, I'll hand over to Michael to get started.

Michael E. Castagna

MannKind Corporation - CEO & Director

Thank you for having us today. I appreciate being back at JPMorgan. It's been a great week and a great conference, and thank you for hosting it this year.

So MannKind, as you saw, is really about paving the future of orphan lung diseases and how we have pivoted the company from what we were known as 31 years of an inhalation diabetes company that was struggling to now really pivoting to a pipeline that has multiple shots on goal, nebulized and dry powders, along with a nice royalty stream with our partnership with United Therapeutics to a diabetes franchise that is growing and has lots of good readouts in the next year.

Our mission is really to give people control of their health and the freedom to live life. As we sit back and looked

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.